FDA update
U.S. Food and Drug Administration (FDA)

FDA Approves Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma

On December 13, 2023, the U.S. Food and Drug Administration (FDA) approved eflornithine (Iwilfin™) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who demonstrated at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy. This represents the first FDA approval of a therapy intended to reduce the risk of relapse in pediatric patients with HRNB.

December 13, 2023